#onty

[maroonwithonem]

Any ships you ship in Kindergarten? :)

I don’t tend to ship stuff very often, but I do enjoy Ted/Penny, nugget/lily, ozzy/madison, Monty/Carla, Felix/redemption arc. You know, stuff like that. I don’t really like to look at stuff just for the ships usually, theres gotta be plot, or a good artstyle/writing style to back it up usually.

Thanks for asking!

[joyfulengineerland]

ZTE F670L V9.0 GPON dual band ONT at Telecomate.com

F670L V9.0 GPON Terminal with 4*GE+1*POTS+2*USB+2.4G/5G WIFI, 4*5dBi antennas, Huawei/ZTE OLT Compatible, 3-5 days delivery, one year warran

[zellikalways]

Family time ! Datang keluarga dari jauh2 smua.. dari purwokerto, bsd sama hamburg ! Selena cenangs ramai orang jenguk ye ! 😘😍😄 #29apr2018 #selena6mo #senangnyajadiibu #iwearmothercare #onty (di Pantai Hillpark , Pantai Permai)

[stockmarketsdaily]

New Post has been published on Stock Markets Daily

New Post has been published on http://www.stockmarketsdaily.com/strong-buy-rating-oncothyreon-inc-nasdaqonty/15036/

Strong Buy Rating: Oncothyreon Inc (NASDAQ:ONTY)

(adsbygoogle = window.adsbygoogle || []).push();

Oncothyreon Inc. (NASDAQ:ONTY) [Trend Analysis] has been making some waves among investors and analysts analysts alike. Therefore we take a look at the current wall street consensus ratings on ONTY.

Analysis

Oncothyreon Inc. (NASDAQ:ONTY) last traded at $3.42 after moving up 0.88% for the trading day. The company last released their quarterly earnings results on 05-11-15 for the period ended Mar-15. The company reported earnings of -$0.06 against a Zack’s research estimate of $0.08. This represents a -175.00% surprise on the expected result.

The current average broker recommendation for Oncothyreon Inc., according to Zack’s research, is 1.50, based on 4 broker ratings. With 1 being a strong buy and 5 being a strong sell, this means that on a consensus basis, analysts currently see Oncothyreon Inc. as a strong buy. The 12 month target consensus price estimate among these analysts for Oncothyreon Inc. is currently at $3.50.

Out of the 4 broker recommendations for ONTY, 3 recommend it as a strong buy, 0 as a buy, 1 as a hold 0 as a sell and 0 as a strong sell.

For the current quarter, the consensus analyst estimate for Oncothyreon Inc. (NASDAQ:ONTY) is -$0.08, with analysts expecting year on year growth for the company of -17.86%

About Oncothyreon Inc. (NASDAQ:ONTY)

Oncothyreon Inc., formerly Biomira Inc. is a clinical-stage biopharmaceutical company focused primarily on the development and commercialization of therapeutic products for the treatment of cancer. The company is currently developing multiple therapeutic candidates designed to target cancer in specific and effective ways. Headquartered in Seattle, Washington, the primary goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. The Company’s lead product candidate is Stimuvax, which is a cancer vaccine in Phase III development for non-small cell lung cancer. Oncothyreon has an exclusive, worldwide collaboration agreement with Merck KGaA of Darmstadt, Germany, for the development and commercialization of Stimuvax. Its pipeline of clinical and preclinical-stage small molecule product candidates includes PX-12, PX-478 and PX-866, from ProlX Pharmaceuticals Corporation.

[edliston]

Oncothyreon Stock Upgraded to Outperform

Wedbush upgraded Oncothyreon stock from Neutral to Outperform.

View Post

[pandafloof]

devlaamseleeuw replied to your photo: Haha… whats up with these angry chibi.. things...

(Aww… poor Onty. D8)

"Aren't I though, Kei? I used to be her favorite. Now I don't even play second fiddle to a partridge... A PARTRIDGE for crying out loud! How humiliating is that?"